171 related articles for article (PubMed ID: 33443847)
1. Comparison of Immunohistochemistry and DNA Sequencing for BRAF V600E Mutation Detection in Mandibular Ameloblastomas.
da Silva Marcelino BMR; Parise GK; do Canto AM; Sassi LM; Sarmento DJS; Costa ALF; Hasséus B; Kjeller G; Schussel JL; Braz-Silva PH
Appl Immunohistochem Mol Morphol; 2021 May-Jun 01; 29(5):390-393. PubMed ID: 33443847
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical and genetic study of BRAF
Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J
Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720
[TBL] [Abstract][Full Text] [Related]
9. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
[TBL] [Abstract][Full Text] [Related]
10. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
[TBL] [Abstract][Full Text] [Related]
12. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
[TBL] [Abstract][Full Text] [Related]
15. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
16. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
[TBL] [Abstract][Full Text] [Related]
17. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
[TBL] [Abstract][Full Text] [Related]
18. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
19. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study.
Martins-de-Barros AV; da Costa Araújo FA; Barros AMI; Dos Santos EGF; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; Neves RFSN; de Hollanda Valente RO; de Oliveira E Silva ED; de Vasconcelos Carvalho M
J Oral Pathol Med; 2024 Apr; 53(4):258-265. PubMed ID: 38494749
[TBL] [Abstract][Full Text] [Related]
20. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.
Bullock M; O'Neill C; Chou A; Clarkson A; Dodds T; Toon C; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Learoyd DL; Capper D; von Deimling A; Clifton-Bligh RJ; Gill AJ
Endocr Relat Cancer; 2012 Dec; 19(6):779-84. PubMed ID: 22997209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]